Literature DB >> 9097954

Inhibition of fibrillin 1 expression using U1 snRNA as a vehicle for the presentation of antisense targeting sequence.

R A Montgomery1, H C Dietz.   

Abstract

This study examines whether the mimicking of selected properties of naturally occurring antisense RNAs in prokaryotes allows efficient inhibition of gene expression by in situ-expressed recombinant molecules in mammalian cells. Prokaryotic regulatory transcripts are expressed at high levels and have hairpin structures at their termini, features reminiscent of small nuclear RNAs (snRNAs) which are abundant and stable in the nucleus of all mammalian cells. A sequence complementary to fibrillin-1 (FBN1) mRNA, interrupted in its center by a hammerhead ribozyme, was substituted for the Sm protein binding site between the stem-loop structures of U1 snRNA. Expression of the chimeric antisense RNA resulted in dramatic inhibition of expression of fibrillin-1 message and protein in stably transfected cultured cells. The inhibitory effect was localized to the nucleus. The biological properties of U1 snRNA may provide a widely applicable vehicle for the in vivo delivery of antisense targeting sequences.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9097954     DOI: 10.1093/hmg/6.4.519

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  19 in total

1.  Reduction of target gene expression by a modified U1 snRNA.

Authors:  S A Beckley; P Liu; M L Stover; S I Gunderson; A C Lichtler; D W Rowe
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

2.  Analysis of inhibitory action of modified U1 snRNAs on target gene expression: discrimination of two RNA targets differing by a 1 bp mismatch.

Authors:  Peng Liu; Amy Gucwa; Mary Louise Stover; Emily Buck; Alexander Lichtler; David Rowe
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

3.  A small nucleolar RNA:ribozyme hybrid cleaves a nucleolar RNA target in vivo with near-perfect efficiency.

Authors:  D A Samarsky; G Ferbeyre; E Bertrand; R H Singer; R Cedergren; M J Fournier
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

4.  Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts.

Authors:  P A Dawson; J C Marini
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

5.  Targeting a KH-domain protein with RNA decoys.

Authors:  Aleksandr V Makeyev; Dawn L Eastmond; Stephen A Liebhaber
Journal:  RNA       Date:  2002-09       Impact factor: 4.942

6.  Assessment of complement C4 gene copy number using the paralog ratio test.

Authors:  Michelle M A Fernando; Lora Boteva; David L Morris; Bi Zhou; Yee Ling Wu; Marja-Liisa Lokki; Chack Yung Yu; John D Rioux; Edward J Hollox; Timothy J Vyse
Journal:  Hum Mutat       Date:  2010-07       Impact factor: 4.878

Review 7.  The molecular genetics of Marfan syndrome and related microfibrillopathies.

Authors:  P N Robinson; M Godfrey
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

8.  Role of metalloprotease disintegrin ADAM12 in determination of quiescent reserve cells during myogenic differentiation in vitro.

Authors:  Yi Cao; Zhefeng Zhao; Joanna Gruszczynska-Biegala; Anna Zolkiewska
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

9.  Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs.

Authors:  L Gorman; D Suter; V Emerick; D Schümperli; R Kole
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

10.  Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome.

Authors:  Daniel P Judge; Nancy J Biery; Douglas R Keene; Jessica Geubtner; Loretha Myers; David L Huso; Lynn Y Sakai; Harry C Dietz
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.